U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

Nxera Pharma Co., Ltd. announces that it has entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. (Holling) for daridorexant in Taiwan. Daridorexant is an oral dual ...

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the growing ...

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the ...